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A Corrigendum on
Cathepsin D Variants Associated With Neurodegenerative Diseases Show Dysregulated
Functionality and Modified α-Synuclein Degradation Properties
by Bunk, J., Prieto Huarcaya, S., Drobny, A., Dobert, J. P., Walther, L., Rose-John, S., et al. (2021).
Front. Cell Dev. Biol. 9:581805. doi: 10.3389/fcell.2021.581805
In the original article, there was a mistake in Figure 1C as published. In the Coomassie brilliant
blue (CBB) protein staining, which was used as additional loading control (besides GAPDH), 11
instead of 10 sample lanes (+ protein ladder) were shown in the original Figure 1C. This mistake
resulted from an additional sample (transfection control), that was loaded on the far right. This
lane was not shown in both immunoblots (CTSD and GAPDH), but accidentally was still shown in
the CBB control. The corrected Figure 1C appears below.
The authors apologize for this error and state that this does not change the scientific conclusions
of the article in any way. The original article has been updated.
Bunk et al. Corrigendum: Analysis of CTSD Variants
FIGURE 1 | Characterization of CTSD variants associated with neurodegenerative diseases in SH-SY5Y CTSD KO cells. (A) Schematic overview of NCL- and
AD-associated CTSD variants analyzed in this study. During protein maturation, the signal peptide (20 aa) and the propeptide (44 aa) are removed, generating an
intermediate form (∼48 kDa) that is further processed in the lysosome into a double-chain mature form comprised of a light chain (∼14 kDa) and a heavy chain (∼34
kDa; symbolized by scissor symbol). Both chains remain associated by hydrophobic interactions. Point mutations found in NCL- and AD- patients located within
different protein parts are shown in different colors (A58V, pink, propeptide; S100F, yellow, light chain; G149V, orange, light chain; F229I, light blue, heavy chain;
Y255X, green, heavy chain; W383C, dark blue, heavy chain; R399H, purple, heavy chain). Aspartates D97 and D295 as part the catalytic site are highlighted
(Continued)
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Bunk et al. Corrigendum: Analysis of CTSD Variants
FIGURE 1 | in red. (B) Crystal structure model of mature CTSD consisting of the light chain (blue) and the heavy chain (gray) [PDB-ID: 4OBZ (Gradler et al., 2014)]. The
active site, consisting of the two aspartates D97 and D295, is shown in red. Other colors indicate disease-associated point mutations within the CTSD protein (same
color code as in A). (C) Representative immunoblot of transiently overexpressed CTSD wildtype (wt) and NCL-/AD-associated CTSD variants, as well as enzymatically
inactive control (D97S) in SH-SY5Y CTSD KO cells. An anti-CTSD antibody was used for the detection of immature (pro- and intermediate form) as well as mature
CTSD (heavy chain, 34 kDa). GAPDH and coomassie brilliant blue (CBB) were used as a loading control. (D) Quantification of western blot signal intensity of mature
CTSD (heavy chain) normalized to GAPDH and expressed relative to CTSD wt (n = 4). (E) Analysis of CTSD activity assessed in whole cell lysates utilizing a fluorogenic
CTSD peptide cleavage assay. The activity was normalized to CTSD wt (n = 4). (F) Representative immunofluorescence pictures of SH-SY5Y CTSD KO cells
expressing CTSD wt or NCL-/AD-associated variants. Cells were visualized by staining of CTSD (green), the lysosomal associated membrane protein LAMP2 (red), and
DAPI as nuclear staining (blue). Scale bar: 20 mm. Confocal images showing the single channels can be found in Supplementary Figure 2. All statistical analyses were
performed using a one-way ANOVA followed by a Tukey’s multiple comparison test. *p < 0.05, **p < 0.01, ****p < 0.0001, n.s., not significant in comparison to wt.
REFERENCES
Gradler, U., Czodrowski, P., Tsaklakidis, C., Klein, M.,
Werkmann, D., Lindemann, S., et al. (2014). Structure-based
optimization of non-peptidic Cathepsin D inhibitors. Bioorg.
Med. Chem. Lett. 24, 4141–4150. doi: 10.1016/j.bmcl.2014.07.
054
Copyright © 2021 Bunk, Prieto Huarcaya, Drobny, Dobert, Walther, Rose-John,
Arnold and Zunke. This is an open-access article distributed under the terms
of the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) and the
copyright owner(s) are credited and that the original publication in this journal
is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Cell and Developmental Biology | www.frontiersin.org 3 June 2021 | Volume 9 | Article 671532
